Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.
相关临床试验
12
6 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2008
进行中（未招募）
5
41.7%
已完成
4
33.3%
尚未招募
1
8.3%
招募中
1
8.3%
终止
1
8.3%
暂无批准数据
- Annovis Bio has partnered with NeuroRPM to implement FDA-cleared AI-enabled digital biomarker monitoring in its ANVS-25002 Parkinson's disease clinical trial using Apple Watch technology. - The NeuroRPM platform continuously monitors key Parkinson's motor symptoms including bradykinesia, tremor, and dyskinesia during daily activities to complement traditional clinical assessments. - The 36-month open-label study aims to enroll 500 participants across 25 U.S. sites to test buntanetap, with 90 patients currently enrolled. - The trial combines digital biomarkers with a highly accurate biomarker test for misfolded phosphorylated alpha-synuclein to comprehensively assess treatment response and disease progression.
- Annovis Bio will initiate a 36-month open-label extension study in January 2026 to evaluate long-term safety and efficacy of buntanetap in 500 Parkinson's disease patients. - The study includes two cohorts: former clinical trial participants and patients receiving deep brain stimulation therapy, addressing an underserved population in clinical research. - This extension study aims to help Annovis meet FDA patient exposure requirements for a future New Drug Application submission, targeting approximately 1,500 total treated patients. - Participants will receive once-daily 30mg oral buntanetap while biomarker data is collected to assess the drug's potential as a disease-modifying treatment.
- Johnson & Johnson terminated its mid-stage AuTonomy study of posdinemab after the anti-tau antibody failed to show statistically significant reduction in cognitive decline compared to placebo in over 500 early-stage Alzheimer's patients. - The failure adds to a string of setbacks for tau-targeting treatments, following previous disappointments from Eli Lilly's LY3372689 and zagotenemab, and Roche's semorinemab programs. - Posdinemab's failure could cast doubt on the therapeutic potential of targeting tau tangles, one of the hallmark features of Alzheimer's disease alongside amyloid plaques. - The setback may impact enthusiasm for similar tau-targeting approaches being developed by Biogen, UCB, Voyager Therapeutics, and other companies in the field.
- Annovis Bio's Phase 3 study demonstrates that buntanetap halted cognitive decline across all early Parkinson's disease patients, with the most significant improvement observed in those with mild dementia. - Approximately 25% of patients exhibited amyloid co-pathology and experienced more pronounced cognitive decline, which was counteracted and reversed by buntanetap treatment. - The therapeutic response was supported by measurable reductions in pTau217, total tau, and brain-derived tau biomarkers, reinforcing the drug's potential for treating overlapping neurodegenerative pathologies. - The findings support Annovis Bio's central principle that neurodegenerative diseases rarely occur in isolation and require therapies targeting multiple neurotoxic proteins.
- Annovis Bio has successfully transferred all patents from the original semi-crystalline form of buntanetap to cover the new crystalline form, securing comprehensive intellectual property protection through 2046. - The company now maintains 13 patent families filed internationally, covering both forms of buntanetap including composition of matter, mechanism of action, multiple indications, and drug combinations. - The crystalline form demonstrates improved solid-state stability with bioequivalent pharmacokinetic properties compared to the original form, as presented at AAIC 2025. - FDA has approved the use of crystal buntanetap for the ongoing pivotal Phase 3 clinical trial in early Alzheimer's disease, with over 75 sites secured across the US.
- The Alzheimer's drug development landscape has expanded significantly beyond anti-amyloid antibodies, with 88 different clinical trials currently recruiting patients and twelve Phase 3 trials expected to report results in 2025. - Several promising approaches are advancing through late-stage trials, including GLP-1 agonist semaglutide from Novo Nordisk and innovative biologics like vaccines and cell therapies targeting both disease modification and symptom management. - Novel therapeutic modalities are gaining traction, including brain-stimulating devices like Cognito's SPECTRIS headset and magnetic stimulation protocols that showed cognitive benefits in Phase 2 trials.
- Annovis Bio's buntanetap demonstrated significant improvements in cognitive function for early Parkinson's disease patients with mild dementia in a Phase III clinical trial, preventing cognitive decline compared to placebo. - While the drug failed to reach its primary endpoint in the total intention-to-treat population, subgroup analysis revealed that 20mg of buntanetap successfully improved both motor and cognitive functions in patients with MMSE scores of 20-26. - Buntanetap will compete with Anavex's blarcamesine and IRLAB Therapeutics' pirepemat in addressing cognitive complications in Parkinson's disease, targeting a significant unmet need identified by key opinion leaders.
- Annovis Bio initiated a Phase 3 trial of buntanetap for early Alzheimer's, aiming to assess both symptomatic and disease-modifying effects over 18 months. - The trial follows positive Phase 2/3 data and has secured initial funding, with plans to enroll over 750 participants across approximately 100 U.S. sites. - AbbVie's tavapadon met its primary endpoint in a Phase 3 trial for early Parkinson's disease, demonstrating significant motor function improvement. - AbbVie plans to submit a New Drug Application to the FDA in 2025, potentially offering a novel treatment option for Parkinson's patients.
- Research in the seven major markets (7MM) increasingly prioritizes disease-modifying therapies (DMTs) and treatments for non-motor symptoms of Parkinson's disease. - 66% of the 93 products in Phase I-III development are prospective neuroprotective agents or DMTs targeting mechanisms like alpha-synuclein aggregation and neuroinflammation. - 26% of pipeline DMTs target alpha-synuclein aggregation, though this approach has faced setbacks, highlighting the complexity of Parkinson's pathogenesis. - There is also growing research into treatments for non-motor symptoms, with 3% of the pipeline specifically targeting Parkinson's disease dementia and psychosis.
- Clinical research in Parkinson's disease (PD) is increasingly focused on disease-modifying therapies (DMTs) to address unmet needs beyond motor symptom management. - 66% of the 93 products in Phase I-III development target key mechanisms like alpha-synuclein aggregation and neuroinflammation to slow disease progression. - Late-stage DMTs include Annovis Bio’s Posiphen and BioVie’s Triolex, targeting alpha-synuclein inhibition and inflammatory mediators, respectively. - Research also emphasizes non-motor symptoms, with agents like Cerevance’s solengepras and IRLAB’s Pirepemat targeting postural instability and PD-dementia.
